Trade Vericel Corp Ord - VCEL CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.09 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Vericel Corp ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 32.46 |
| Open* | 33.3 |
| 1-Year Change* | 30.54% |
| Day's Range* | 33.3 - 34.41 |
| 52 wk Range | 17.30-39.90 |
| Average Volume (10 days) | 259.04K |
| Average Volume (3 months) | 7.79M |
| Market Cap | 1.57B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 47.64M |
| Revenue | 178.18M |
| EPS | -0.28 |
| Dividend (Yield %) | N/A |
| Beta | 1.76 |
| Next Earnings Date | Nov 7, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 21, 2023 | 34.14 | 1.38 | 4.21% | 32.76 | 34.45 | 32.76 |
| Sep 20, 2023 | 32.46 | -0.50 | -1.52% | 32.96 | 34.10 | 32.42 |
| Sep 19, 2023 | 33.63 | 0.66 | 2.00% | 32.97 | 33.98 | 32.97 |
| Sep 18, 2023 | 33.91 | -0.03 | -0.09% | 33.94 | 34.13 | 33.27 |
| Sep 15, 2023 | 34.23 | -0.69 | -1.98% | 34.92 | 35.63 | 34.02 |
| Sep 14, 2023 | 35.67 | -1.01 | -2.75% | 36.68 | 36.82 | 35.48 |
| Sep 13, 2023 | 36.68 | 0.17 | 0.47% | 36.51 | 37.71 | 36.51 |
| Sep 12, 2023 | 36.46 | 4.02 | 12.39% | 32.44 | 36.79 | 32.44 |
| Sep 11, 2023 | 34.03 | 1.52 | 4.68% | 32.51 | 34.18 | 32.51 |
| Sep 8, 2023 | 32.65 | 0.61 | 1.90% | 32.04 | 32.77 | 32.04 |
| Sep 7, 2023 | 32.82 | 0.74 | 2.31% | 32.08 | 33.73 | 32.06 |
| Sep 6, 2023 | 33.44 | 1.37 | 4.27% | 32.07 | 33.49 | 32.06 |
| Sep 5, 2023 | 32.50 | -0.82 | -2.46% | 33.32 | 33.36 | 32.15 |
| Sep 1, 2023 | 33.83 | 1.03 | 3.14% | 32.80 | 33.95 | 32.80 |
| Aug 31, 2023 | 32.79 | 0.63 | 1.96% | 32.16 | 33.16 | 32.16 |
| Aug 30, 2023 | 32.50 | 0.59 | 1.85% | 31.91 | 32.57 | 31.91 |
| Aug 29, 2023 | 32.24 | 0.33 | 1.03% | 31.91 | 32.52 | 31.91 |
| Aug 28, 2023 | 32.02 | 0.28 | 0.88% | 31.74 | 32.98 | 31.74 |
| Aug 25, 2023 | 32.43 | 0.27 | 0.84% | 32.16 | 32.95 | 32.14 |
| Aug 24, 2023 | 32.31 | -0.45 | -1.37% | 32.76 | 32.91 | 32.09 |
Vericel Corp Ord Events
| Time (UTC) | Country | Event |
|---|---|---|
| Tuesday, November 7, 2023 | ||
| Time (UTC) 13:30 | Country US
| Event Q3 2023 Vericel Corp Earnings Release Q3 2023 Vericel Corp Earnings ReleaseForecast -Previous - |
| Wednesday, February 21, 2024 | ||
| Time (UTC) 13:30 | Country US
| Event Q4 2023 Vericel Corp Earnings Release Q4 2023 Vericel Corp Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 164.365 | 156.184 | 124.179 | 117.85 | 90.857 |
| Revenue | 164.365 | 156.184 | 124.179 | 117.85 | 90.857 |
| Cost of Revenue, Total | 54.577 | 50.159 | 39.951 | 37.571 | 32.16 |
| Gross Profit | 109.788 | 106.025 | 84.228 | 80.279 | 58.697 |
| Total Operating Expense | 181.423 | 164.038 | 121.807 | 129.101 | 95.604 |
| Selling/General/Admin. Expenses, Total | 106.903 | 97.592 | 68.836 | 61.139 | 49.007 |
| Research & Development | 19.943 | 16.287 | 13.02 | 30.391 | 13.599 |
| Unusual Expense (Income) | 0 | 0 | 0.838 | ||
| Operating Income | -17.058 | -7.854 | 2.372 | -11.251 | -4.747 |
| Interest Income (Expense), Net Non-Operating | 0.975 | 0.22 | 0.685 | 1.606 | -3.359 |
| Other, Net | 0.095 | 0.052 | -0.013 | -0.02 | -0.031 |
| Net Income Before Taxes | -15.988 | -7.582 | 3.044 | -9.665 | -8.137 |
| Net Income After Taxes | -16.709 | -7.471 | 2.864 | -9.665 | -8.137 |
| Net Income Before Extra. Items | -16.709 | -7.471 | 2.864 | -9.665 | -8.137 |
| Net Income | -16.709 | -7.471 | 2.864 | -9.665 | -8.137 |
| Total Adjustments to Net Income | 0 | ||||
| Income Available to Common Excl. Extra. Items | -16.709 | -7.471 | 2.864 | -9.665 | -8.137 |
| Income Available to Common Incl. Extra. Items | -16.709 | -7.471 | 2.864 | -9.665 | -8.137 |
| Diluted Net Income | -16.709 | -7.471 | 2.864 | -9.665 | -8.137 |
| Diluted Weighted Average Shares | 47.13 | 46.472 | 47.282 | 44.18 | 40.242 |
| Diluted EPS Excluding Extraordinary Items | -0.35453 | -0.16076 | 0.06057 | -0.21876 | -0.2022 |
| Diluted Normalized EPS | -0.35453 | -0.16076 | 0.06057 | -0.21876 | -0.18138 |
| Total Extraordinary Items |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 45.922 | 41.017 | 52.694 | 38.551 | 37.046 |
| Revenue | 45.922 | 41.017 | 52.694 | 38.551 | 37.046 |
| Cost of Revenue, Total | 15.981 | 14.497 | 14.445 | 13.318 | 14.192 |
| Gross Profit | 29.941 | 26.52 | 38.249 | 25.233 | 22.854 |
| Total Operating Expense | 51.883 | 49.194 | 46.609 | 45.339 | 46.128 |
| Selling/General/Admin. Expenses, Total | 30.649 | 29.485 | 26.919 | 26.975 | 27.144 |
| Research & Development | 5.253 | 5.212 | 5.245 | 5.046 | 4.792 |
| Operating Income | -5.961 | -8.177 | 6.085 | -6.788 | -9.082 |
| Interest Income (Expense), Net Non-Operating | 0.946 | 0.694 | 0.54 | 0.237 | 0.128 |
| Other, Net | -0.005 | -0.012 | -0.003 | -0.005 | -0.009 |
| Net Income Before Taxes | -5.02 | -7.495 | 6.622 | -6.556 | -8.963 |
| Net Income After Taxes | -5.02 | -7.495 | 5.922 | -6.577 | -8.963 |
| Net Income Before Extra. Items | -5.02 | -7.495 | 5.922 | -6.577 | -8.963 |
| Net Income | -5.02 | -7.495 | 5.922 | -6.577 | -8.963 |
| Income Available to Common Excl. Extra. Items | -5.02 | -7.495 | 5.922 | -6.577 | -8.963 |
| Income Available to Common Incl. Extra. Items | -5.02 | -7.495 | 5.922 | -6.577 | -8.963 |
| Diluted Net Income | -5.02 | -7.495 | 5.922 | -6.577 | -8.963 |
| Diluted Weighted Average Shares | 47.572 | 47.387 | 47.232 | 47.182 | 47.117 |
| Diluted EPS Excluding Extraordinary Items | -0.10552 | -0.15817 | 0.12538 | -0.1394 | -0.19023 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.10552 | -0.15817 | 0.12538 | -0.1394 | -0.19023 |
| Total Adjustments to Net Income |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 186.866 | 158.462 | 123.56 | 111.655 | 112.783 |
| Cash and Short Term Investments | 119.538 | 103.398 | 75.807 | 69.718 | 82.924 |
| Cash & Equivalents | 51.067 | 68.33 | 33.62 | 26.889 | 18.286 |
| Total Receivables, Net | 46.539 | 37.437 | 34.504 | 32.168 | 23.454 |
| Accounts Receivable - Trade, Net | 46.539 | 37.437 | 34.504 | 32.168 | 23.454 |
| Total Inventory | 15.986 | 13.381 | 9.356 | 6.816 | 3.558 |
| Other Current Assets, Total | 4.803 | 4.246 | 3.893 | 2.953 | 2.847 |
| Total Assets | 273.003 | 243.705 | 205.608 | 153.238 | 118.689 |
| Property/Plant/Equipment, Total - Net | 57.372 | 59.028 | 57.738 | 32.247 | 5.906 |
| Property/Plant/Equipment, Total - Gross | 75.674 | 73.35 | 69.124 | 41.467 | 13.411 |
| Accumulated Depreciation, Total | -18.302 | -14.322 | -11.386 | -9.22 | -7.505 |
| Intangibles, Net | 7.5 | ||||
| Total Current Liabilities | 37.463 | 26.052 | 22.483 | 19.795 | 14.792 |
| Accounts Payable | 16.93 | 9.016 | 6.755 | 6.345 | 7.108 |
| Accrued Expenses | 20.492 | 16.995 | 15.687 | 13.409 | 6.93 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.041 | 0.041 | 0.041 | 0.041 | 0 |
| Other Current Liabilities, Total | 0.754 | ||||
| Total Liabilities | 80.731 | 73.243 | 71.348 | 42.147 | 16.458 |
| Total Long Term Debt | 0 | 0.044 | 0.076 | 0.11 | 0 |
| Long Term Debt | 0 | ||||
| Other Liabilities, Total | 43.268 | 47.147 | 48.789 | 22.242 | 1.666 |
| Total Equity | 192.272 | 170.462 | 134.26 | 111.091 | 102.231 |
| Preferred Stock - Non Redeemable, Net | |||||
| Common Stock | 593.245 | 553.902 | 510.061 | 489.749 | 471.18 |
| Retained Earnings (Accumulated Deficit) | -399.995 | -383.286 | -375.815 | -378.679 | -368.91 |
| Treasury Stock - Common | |||||
| Total Liabilities & Shareholders’ Equity | 273.003 | 243.705 | 205.608 | 153.238 | 118.689 |
| Total Common Shares Outstanding | 47.253 | 46.88 | 45.804 | 44.864 | 43.578 |
| Total Preferred Shares Outstanding | |||||
| Short Term Investments | 68.471 | 35.068 | 42.187 | 42.829 | 64.638 |
| Other Equity, Total | -0.978 | -0.154 | 0.014 | 0.021 | -0.039 |
| Long Term Investments | 19.962 | 25.687 | 24.099 | 9.247 | |
| Other Long Term Assets, Total | 1.303 | 0.528 | 0.211 | 0.089 | |
| Capital Lease Obligations | 0 | 0.044 | 0.076 | 0.11 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 177.545 | 186.866 | 166.375 | 155.094 | 151.88 |
| Cash and Short Term Investments | 119.276 | 119.538 | 110.94 | 100.692 | 100.547 |
| Cash & Equivalents | 61.834 | 51.067 | 65.216 | 56.054 | 55.659 |
| Short Term Investments | 57.442 | 68.471 | 45.724 | 44.638 | 44.888 |
| Total Receivables, Net | 38.359 | 46.539 | 34.296 | 33.664 | 31.855 |
| Accounts Receivable - Trade, Net | 38.359 | 46.539 | 34.296 | 33.664 | 31.855 |
| Total Inventory | 15.37 | 15.986 | 16.729 | 15.929 | 14.385 |
| Other Current Assets, Total | 4.54 | 4.803 | 4.41 | 4.809 | 5.093 |
| Total Assets | 265.096 | 273.003 | 248.017 | 244.815 | 240.288 |
| Property/Plant/Equipment, Total - Net | 59.048 | 57.372 | 58.546 | 59.502 | 59.104 |
| Property/Plant/Equipment, Total - Gross | 78.25 | 75.674 | 75.81 | 75.752 | 74.299 |
| Accumulated Depreciation, Total | -19.202 | -18.302 | -17.264 | -16.25 | -15.195 |
| Long Term Investments | 19.91 | 19.962 | 21.739 | 23.718 | 22.803 |
| Other Long Term Assets, Total | 1.249 | 1.303 | 1.357 | 6.501 | 6.501 |
| Total Current Liabilities | 28.753 | 37.463 | 27.004 | 25.014 | 21.731 |
| Accounts Payable | 11.125 | 16.93 | 8.113 | 9.684 | 7.75 |
| Accrued Expenses | 17.608 | 20.492 | 18.85 | 15.289 | 13.94 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.02 | 0.041 | 0.041 | 0.041 | |
| Total Liabilities | 71.118 | 80.731 | 70.18 | 69.999 | 67.803 |
| Total Long Term Debt | 0 | 0 | 0 | 0.021 | 0.019 |
| Capital Lease Obligations | 0 | 0 | 0.021 | 0.019 | |
| Other Liabilities, Total | 42.365 | 43.268 | 43.176 | 44.964 | 46.053 |
| Total Equity | 193.978 | 192.272 | 177.837 | 174.816 | 172.485 |
| Common Stock | 602.104 | 593.245 | 584.9 | 575.011 | 563.475 |
| Retained Earnings (Accumulated Deficit) | -407.49 | -399.995 | -405.917 | -399.34 | -390.377 |
| Other Equity, Total | -0.636 | -0.978 | -1.146 | -0.855 | -0.613 |
| Total Liabilities & Shareholders’ Equity | 265.096 | 273.003 | 248.017 | 244.815 | 240.288 |
| Total Common Shares Outstanding | 47.507 | 47.253 | 47.201 | 47.141 | 47.081 |
| Other Current Liabilities, Total | 0.041 | ||||
| Intangibles, Net | 7.344 | 7.5 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -16.709 | -7.471 | 2.864 | -9.665 | -8.137 |
| Cash From Operating Activities | 17.687 | 29.04 | 17.572 | -7.183 | -0.412 |
| Cash From Operating Activities | 3.981 | 2.965 | 2.383 | 1.744 | 1.426 |
| Non-Cash Items | 41.624 | 39.7 | 18.699 | 15.398 | 10.084 |
| Cash Interest Paid | 0.109 | 0.004 | 0.006 | 0 | 2.23 |
| Changes in Working Capital | -11.209 | -6.154 | -6.374 | -14.66 | -3.785 |
| Cash From Investing Activities | -36.206 | -3.501 | -17.16 | 10.615 | -67.027 |
| Capital Expenditures | -7.596 | -7.915 | -2.626 | -2.616 | -2.678 |
| Other Investing Cash Flow Items, Total | -28.61 | 4.414 | -14.534 | 13.231 | -64.349 |
| Cash From Financing Activities | 1.045 | 9.171 | 6.441 | 5.26 | 58.863 |
| Financing Cash Flow Items | -2.607 | -2.013 | -0.191 | -0.026 | -0.71 |
| Issuance (Retirement) of Stock, Net | 3.652 | 11.184 | 6.632 | 5.286 | 77.105 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | -17.532 | ||
| Foreign Exchange Effects | |||||
| Net Change in Cash | -17.474 | 34.71 | 6.853 | 8.692 | -8.576 |
| Cash Taxes Paid | 0 | 0.379 | 0 | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -7.495 | -16.709 | -22.631 | -16.054 | -7.091 |
| Cash From Operating Activities | 7.86 | 17.687 | 10.712 | 6.611 | 3.468 |
| Cash From Operating Activities | 1.158 | 3.981 | 2.942 | 1.928 | 0.873 |
| Non-Cash Items | 9.619 | 41.624 | 32.925 | 22.812 | 10.805 |
| Cash Interest Paid | 0 | ||||
| Changes in Working Capital | 4.578 | -11.209 | -2.524 | -2.075 | -1.119 |
| Cash From Investing Activities | 2.8 | -36.206 | -14.477 | -13.666 | -10.669 |
| Capital Expenditures | -8.913 | -7.596 | -6.471 | -5.062 | -3.081 |
| Other Investing Cash Flow Items, Total | 11.713 | -28.61 | -8.006 | -8.604 | -7.588 |
| Cash From Financing Activities | 0.107 | 1.045 | 0.44 | 0.752 | 0.503 |
| Financing Cash Flow Items | -2.118 | -2.607 | -2.6 | -1.459 | -0.962 |
| Issuance (Retirement) of Stock, Net | 2.225 | 3.652 | 3.04 | 2.211 | 1.465 |
| Net Change in Cash | 10.767 | -17.474 | -3.325 | -6.303 | -6.698 |
| Issuance (Retirement) of Debt, Net | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Vericel Corp Ord Company profile
About Vericel Corp
Vericel Corporation is a commercial-stage biopharmaceutical company. The Company specializes in cell therapies and specialty biologics for the sports medicine and severe burn care. It operates in one reportable segment, the research, product development, manufacture, and distribution of cellular therapies for use in the treatment of specific diseases. It markets two autologous cell therapy products in the United States, which includes MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The MACI is an autologous cellularized scaffold product indicated for the repair of symptomatic, single, or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. The Epicel is a permanent skin replacement humanitarian use device (HUD) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area (TBSA).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Vericel Corp revenues increased 26% to $156.2M. Net loss totaled $7.5M vs. income of $2.9M. Revenues reflect MACI segment increase of 18% to $111.6M, Epicel segment increase of 51% to $41.5M. Net loss reflects Stock-based Compensation in SGA increase from $10M to $26.5M (expense), Other Selling , General Expense increase of 21% to $71.1M (expense).
Equity composition
Common Stock no Par, 3/11, 62.5M auth., 38,618,037 issd. Insiders control approx. 0.63%. IPO: 2/97, 3M shares @ $7 byCowen & Company. 02/10 1-for-8 reverse split. 10/13, 1-for-20 Reverse Stock split.
| Industry: | Biopharmaceuticals |
64 Sidney St
CAMBRIDGE
MASSACHUSETTS 02139-4170
US
Income Statement
- Annual
- Quarterly
News
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com